Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

rrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, the Novartis Group offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. The Novartis Group is the only company with leading positions in each of these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.us.novartis.com.

* Known as Glivec® (imatinib) outside the US, Canada and Israel.

References

(1) Ghobrial, et al. A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia. 51st American Society of Hematology Annual Meeting and Exposition, New Orleans, LA. December 5-8, 2009.

(2) Younes, et al. Efficacy of Panobinostat in Phase II Study in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL) After High-Dose Chemotherapy with Autologous Stem Cell Transplant. 51st Ameri
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Research and Markets  has announced the addition of ... their offering. Global Market Report of Pralmorelin ... and regionally ( Europe , Asia ... Latin America etc.). It captures Pralmorelin market trends, ... on three primary areas; manufacture methods & technology development, market ...
(Date:8/20/2014)... Ariz. , Aug. 20, 2014   ... the  Roche  Group, today announced that its VENTANA ... CE marked in the European Union for routine ... The system, consisting of VENTANA Virtuoso software coupled ... VENTANA iScan HT slide scanner, provides automated digital ...
(Date:8/20/2014)... PHOENIX , Aug. 20, 2014 /PRNewswire-USNewswire/ ... next-generation sequencing and proteomic diagnostics and biomarker driven ... collaboration with TESARO, Inc.  Paradigm will use its ... from clinical trials to better predict which patients ... may lead to more successful clinical trial outcomes ...
Breaking Medicine Technology:Global Market Report of Pralmorelin 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
(Date:8/21/2014)... According to new market research ... Food & Beverage, Personal care & Pharmaceutical) & ... Electronics, Textile) & Geography - Global Trends & ... polylactic acid markets and segments with analyses and ... on their sub-segments, in terms of value and ...
(Date:8/21/2014)... San Luis Obispo, CA (PRWEB) August 21, 2014 ... July/August edition of Current Pedorthics, a bi-monthly publication of the ... the field of pedorthics. , Bunion Bootie ... as an alternative solution for bunion sufferers and their pain. ... be worn in nearly any shoe to eliminate the friction ...
(Date:8/21/2014)... WA (PRWEB) August 21, 2014 While ... Grant, found it hard to stay focused on his ... and mosquitoes. The constant whine, slapping and continual need ... researching innovative methods to stay protected from insects while ... successful career in the Financial Services/Investment Banking Industry, decided ...
(Date:8/21/2014)... 2014 Atlantic Information Services, Inc. (AIS) ... News and The AIS Report on Blue Cross & ... Blue Shield Association or its member companies) — is ... in AIS’s Management Insight Series. Bundled Payment Models: ... two insurers — Horizon Healthcare Services, Inc. and Arkansas ...
(Date:8/21/2014)... 2014 AttorneyOne.com, a recognized authority on ... information from the FDA on Dianeal Low Calcium ... announced on August 15, that two lots of Dianeal ... 5000mL (Ambu-Flex II), by Baxter International Inc., are ... , The reason for the recall is the ...
Breaking Medicine News(10 mins):Health News:Lactic Acid Market Worth $3,577.5 Million & Polylactic Acid Market Worth $4,840.1 Million by 2019 – New Report 2Health News:Lactic Acid Market Worth $3,577.5 Million & Polylactic Acid Market Worth $4,840.1 Million by 2019 – New Report 3Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3Health News:Financial VP Fights Pesky Bugs with Launch of Biteback Sports Insect Shield® Golf Apparel 2Health News:New AIS Report Highlights Two Case Studies of Bundled Payment Models 2Health News:Dianeal Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II) Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... as the Best in GI and Endoscopy Nursing at ... Society of Gastroenterology Nurses and Associates, Inc. (SGNA) is ... series of annual awards that recognize their dedication to ... of these four distinguished awards represent the best in ...
... Calif., May 15 ChromaDex Corporation, (OTC Bulletin ... and contract research, today announced financial results for ... calculated in accordance with U.S. Generally Accepted Accounting ... attributable to common stockholders of $0.01 per share ...
... Cimzia(R) (certolizumab pegol) now offered in an innovative ... GRIPS(R)ATLANTA, May 15 - UCB today announced that ... Necrosis Factor) approved in the U.S. for reducing ... clinical response in adult patients with moderate to ...
... it has been known that aspirin is beneficial to ... of the many different types of aspirin is likely ... led by Dr. Sean Nordt from the University of ... to a group of volunteer research subjects: regular aspirin ...
... May 15 Endocare, Inc. (Nasdaq: ENDO ... development of minimally invasive technologies used by urologists and ... results for the first quarter ended March 31, 2009. ... increase in revenue and strong margins.Total revenues for the ...
... Bruno E. Gerber is recognized in Continental Who,s ... Consultant Orthopedic Surgeon with a special interest in ... lower limbs. He also is employed as medical ... regarding innovative orthopedic laser treatment.Dr. Gerber undertook his ...
Cached Medicine News:Health News:SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards 2Health News:SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards 3Health News:SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards 4Health News:ChromaDex Reports 2009 Q1 Financial Results 2Health News:ChromaDex Reports 2009 Q1 Financial Results 3Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 2Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 3Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 4Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 5Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 6Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 7Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 8Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 9Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 10Health News:Endocare Reports 2009 First Quarter Financial Results 2Health News:Endocare Reports 2009 First Quarter Financial Results 3Health News:Endocare Reports 2009 First Quarter Financial Results 4Health News:Endocare Reports 2009 First Quarter Financial Results 5Health News:Endocare Reports 2009 First Quarter Financial Results 6Health News:Endocare Reports 2009 First Quarter Financial Results 7Health News:Endocare Reports 2009 First Quarter Financial Results 8Health News:Endocare Reports 2009 First Quarter Financial Results 9Health News:Endocare Reports 2009 First Quarter Financial Results 10Health News:Endocare Reports 2009 First Quarter Financial Results 11Health News:Continental Who's Who Executive Press Release: Dr. Bruno E. Gerber - Medical Professional 2
... The BiPAP Pro with Bi-Flex bi-level system, ... that the BiPAP Pro takes to change ... Digital Auto-Trak Sensitivity™ which automatically triggers the ... pressures based on the patients breathing rhythm. ...
... Electrophoresis System (PGGE) is designed to ... density lipoproteins (LDL) and high density ... using nondenaturing pore gradient gel electrophoresis. ... short DNA sequencing runs. Temperature control ...
This control is intended for monitoring cell counts in patient cerebrospinal fluid samples, performed manually using a hemocytometer. Spinalscopics is fortified to target levels with purified chemica...
... Suitable for use with Leica ... bilirubinometers (pediatric) and all automated ... including Aeroset, AU Series, Cobas, ... These controls contain purified bilirubin ...
Medicine Products: